[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-354782-105":59,"doc-detail-354782-en":131},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":124,"head_meta":126,"extra_data":128,"updated_unix":130},105,"en","clinicopathological-features-immunophenotyping-and-immunohistochemical-biomarkers-associated-with-germline-brca12-variants-in-breast-cancer-a-retrospective-cohort-of-265-patients","Clinicopathological features, immunophenotyping, and immunohistochemical biomarkers associated with germline BRCA1/2 variants in breast cancer - a retrospective cohort of 265 patients","","Breast cancer progression and treatment response depend on germline BRCA1/2 variant status, and emerging PARP inhibitor strategies make the clinical interpretation of these variants increasingly important. A retrospective cohort of 265 patients with invasive breast cancer was tested for germline pathogenic or likely pathogenic BRCA1/2 variants and linked to clinicopathological traits, immunophenotypes, and outcomes. BRCA1/2 pathogenic variants correlated with distinct clinicopathological features, enrichment of triple-negative breast cancer, and worse prognosis. Integrating BRCA1/2 testing with IHC biomarkers, including PD-L1 and p53, may refine risk stratification and support individualized therapy.",{"@graph":69,"@context":123},[70,84,106],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/clinicopathological-features-immunophenotyping-and-immunohistochemical-biomarkers-associated-with-germline-brca12-variants-in-breast-cancer-a-retrospective-cohort-of-265-patients/354782/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/clinicopathological-features-immunophenotyping-and-immunohistochemical-biomarkers-associated-with-germline-brca12-variants-in-breast-cancer-a-retrospective-cohort-of-265-patients/354782.png","ImageObject",300,407,{"name":92,"@type":93},"pixelkiddo","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-11-17","2026-09-22",true,{"@type":102,"interactionType":103,"userInteractionCount":105},"InteractionCounter",{"@type":104},"ViewAction",11,{"@type":107,"mainEntity":108},"FAQPage",[109,115,119],{"name":110,"@type":111,"acceptedAnswer":112},"What was the study design and sample size?","Question",{"text":113,"@type":114},"The study retrospectively enrolled 265 patients with invasive breast cancer and assessed germline BRCA1/2 variants.","Answer",{"name":116,"@type":111,"acceptedAnswer":117},"How do germline BRCA1/2 pathogenic variants relate to tumor characteristics and subtype?",{"text":118,"@type":114},"Germline pathogenic/likely pathogenic BRCA1/2 variants were associated with distinct clinicopathological features and enrichment of triple-negative breast cancer.",{"name":120,"@type":111,"acceptedAnswer":121},"Which immunohistochemical biomarkers were discussed for risk stratification?",{"text":122,"@type":114},"The text highlights integrating BRCA1/2 testing with IHC biomarkers, including PD-L1 in triple-negative breast cancer and other markers such as p53.","https://schema.org",{"og:url":83,"og:type":125,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":127,"canonical":83},"index,follow",{"doc_id":129,"site_id":62},354782,1790516333,{"code":4,"msg":5,"data":132},{"doc_id":129,"user_id":133,"nickname":92,"user_avatar":134,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":135,"file_id":136,"file_url":137,"file_type":138,"file_size":139,"view_count":105,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":52,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":145,"preview_page_count":19,"preview_urls":146},962090883892,"https://ap-avatar.wpscdn.com/avatar/e00115db34f3e0f11b?x-image-process=image/resize,m_fixed,w_180,h_180&k=1790152879550218658","[www. nature.com/scientificreports](www. nature.com/scientificreports)  \nOPEN  \nClinicopathological features, immunophenotyping, and immunohistochemical biomarkers associated with germline BRCA1/2 variants in breast cancer: a retrospective cohort of 265 patients  \nFeifei Huang1, Zhongyi Tong2 & Yi Jiang2􀀍  \nBreast cancer (BC) progression and treatment response are influenced by germline BRCA1/2 (gBRCA) variant status. Carrying BRCA1/2 gene variants increases an individual’s risk of developing breast cancer. With the advent of poly ADP-ribose polymerase (PARP) inhibitors, these patients may achieve disease control and effective treatment. However, the clinicopathological characteristics and immunophenotypes associated with this gene in breast cancer remain incompletely understood. A total of 265 patients with invasive breast cancer were retrospectively enrolled and tested for gBRCA variants. Germline pathogenic/likely pathogenic BRCA1/2 variants are associated with distinct clinicopathological features, triple-negative breast cancer (TNBC) enrichment, and adverse prognosis. Integrating BRCA1/2 testing with immunohistochemical (IHC) biomarkers (including programmed death-ligand 1(PD-L1) inTNBC) may help refine risk stratification and inform individualized therapy.  \nKeywords Breast cancer, Germline BRCA1/2, Triple-negative breast cancer, PD-L1, p53, Prognosis  \nBreast cancer is the most frequently diagnosed malignancy among women worldwide and remains a major cause of cancer-related mortality1,2. Immunophenotyping profiling based on estrogen receptor (ER), progesterone receptor (PR), human epidermal growth factor receptor 2 (HER2), and the proliferation marker Ki-67 enables clinical subtype classification that guides therapeutic decision-making and prognostic assessment3. Beyond these core markers, additional biomarkers and genomic alterations—including germline BRCA1/2 (gBRCA) variants, tumor protein P53 (TP53) alterations, programmed death-ligand 1 (PD-L1) expression, and tumor-infiltrating lymphocytes (TIL)—have gained increasing importance for risk assessment and treatment selection4–7.  \nAmong the breast cancer population, 5%–10% of patients have clear hereditary genetic variants and are classified as having hereditary breast cancer (HBC) . Susceptibility genes associated with this type of cancer include BRCA1/2, ATM, CDH1, LKB1, PTEN, PALB2, TP53, and CHEK28,9. Different gene variants exhibit specific associations with breast cancer. For instance, after neoadjuvant chemotherapy for triple-negative breast cancer, patients with CDH1 variants show a higher rate of pathological complete response (pCR) . Variants in PALB2/MLH1 increase the risk of developing bilateral breast cancer, while ATM variants are more strongly associated with a family history of cancer8–10. Under the influence of these susceptibility genes, this breast cancer population is more likely to develop ovarian cancer, with a comorbidity rate of 7.3%10, 11. Among all genetic variants, BRCA1/2 variants account for 15% and exhibit stronger mutational effects than variants in other genes12. Individuals carrying such variants have a 40%–80% probability of developing breast cancer13, 14. Studies  \n1Department of Pathology, Shenzhen People’s Hospital (The Second Clinical Medical College, Jinan University; The First Affiliated Hospital, Southern University of Science and Technology), Shenzhen 518020, China. 2Department of Pathology, The Second Xiangya Hospital, Central South University, Changsha 410011, Hunan, China. 􀀍 email: [jiangyi76@csu.edu.cn](jiangyi76@csu.edu.cn)  \n[www. nature.com/scientificreports](www. nature.com/scientificreports)  \nhave shown that breast cancer patients with BRCA variants tend to have a poorer prognosis. This underscores the urgent need for the further implementation of precision diagnosis and treatment strategies in clinical practice. Pathogenic germline variants in BRCA1/2 may influence tumor biology and treatment sensitivity15–17. As k","cbCaius3SjiFKZkS","https://ap.wps.com/l/cbCaius3SjiFKZkS","pdf",2797907,"English","# Clinicopathological context of germline BRCA1/2 variants\n## Study design and patient cohort\n## Associations with clinicopathological features\n## Immunophenotyping and IHC biomarkers\n## Prognostic and therapeutic implications","[{\"question\":\"What was the study design and sample size?\",\"answer\":\"The study retrospectively enrolled 265 patients with invasive breast cancer and assessed germline BRCA1/2 variants.\"},{\"question\":\"How do germline BRCA1/2 pathogenic variants relate to tumor characteristics and subtype?\",\"answer\":\"Germline pathogenic/likely pathogenic BRCA1/2 variants were associated with distinct clinicopathological features and enrichment of triple-negative breast cancer.\"},{\"question\":\"Which immunohistochemical biomarkers were discussed for risk stratification?\",\"answer\":\"The text highlights integrating BRCA1/2 testing with IHC biomarkers, including PD-L1 in triple-negative breast cancer and other markers such as p53.\"}]","Clinicopathological features, immunophenotyping, and immunohistochemical biomarkers associated with germline BRCA1/2 variants in breast cancer - a retrospective cohort of 265 patients | PDF",1790113833,25,[147,151,155,159],{"page_no":8,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/23fa727a4060b184178d3df9717c8973.webp",983,1291,{"page_no":14,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/d008f0626d55a29b008e57c3db40ba78.webp",982,1290,{"page_no":81,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/196d34346ffabd9f0e9cccf06fd2b0ff.webp",981,1289,{"page_no":19,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/c1db370ed6785f6cea92bfb191944bbf.webp",980,1287]